Asia-Pacific In-Vitro Fertilization (IVF) Market Size- By Cycle Type, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033

Description

Asia-Pacific In-Vitro Fertilization (IVF) Market Introduction and Overview

According to SPER market research, 'Asia-Pacific In-Vitro Fertilization (IVF) Market Size- By Cycle Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033'state that the Asia-Pacific In-Vitro Fertilization (IVF) Market is predicted to reach USD 63.52 Billion by 2033 with a CAGR of 17.24%.

The term "in vitro fertilisation" (IVF) is a medical procedure where sperm fertilise an egg outside of the body. Couples who have not been able to conceive naturally because of infertility, reproductive problems, or genetic issues are usually the ones who use this approach. IVF tests, which include a variety of diagnostic procedures and assessments to assist identify potential problems, optimise treatment plans, and raise the odds of successful fertilisation and pregnancy, are an essential element of the IVF process.

The Asia-Pacific IVF services industry is expected to grow more slowly as a result of the COVID-19 pandemic. Numerous nations implemented statewide lockdowns, which had a direct effect on fertility tourism due to the cancellation of flights, travel restrictions and quarantines, prohibitions on holding any kind of indoor or outdoor event, and declarations of emergencies. Growth in the market is hampered by a decline in infertility consultations and a large decline in revenue during COVID-19.

Scope of the Report:

Report Metric Details

Market size available for years 2019-2033

Base year considered 2022

Forecast period 2023-2033

Segments covered By Cycle Type, By End User

Regions covered Australia, China, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Vietnam, Rest of Asia-Pacific

Companies Covered Alcon, Bausch Health Companies Inc., Carl Zeiss AG, Cooper Companies, Johnson & Johnson, MaxiVision Eye Hospital, Rayner Surgical Group Limited, Schwind eye-tech-solutions GmbH & co.kg., STAAR Surgical Company, Ziemer Group AG, Others

APAC In-Vitro Fertilization (IVF) Market Segmentation

By Cycle Type: Based on the Cycle Type, Asia-Pacific In-Vitro Fertilization (IVF) Market is segmented as; Donor Egg IVF Cycle, Fresh Cycle (Non-Donor), Thawed IVF Cycle (Non-Donor).

By End User: Based on the End User, Asia-Pacific In-Vitro Fertilization (IVF) Market is segmented as; Clinical Research Institutes, Fertility Clinics, Hospitals, Surgical Centers.

By Region: This research also includes data for Australia, China, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Philippines, Singapore, South Korea, Thailand, Vietnam, Rest of Asia-Pacific.

Product Code: HLCA2424

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
- 2.1.1. Secondary Data
- 2.1.2. Primary Data
- 2.1.3. SPER's internal database
- 2.1.4. Premium insight from KOL's
2.2. Market size estimation
- 2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
- 4.1.1. Drivers
- 4.1.2. Restraints
- 4.1.3. Opportunities
- 4.1.4. Challenges
4.2. COVID-19 Impacts of the Asia-Pacific In-Vitro Fertilization (IVF) Market

5. Market variable and outlook

5.1. SWOT Analysis
- 5.1.1. Strengths
- 5.1.2. Weaknesses
- 5.1.3. Opportunities
- 5.1.4. Threats
5.2. PESTEL Analysis
- 5.2.1. Political Landscape
- 5.2.2. Economic Landscape
- 5.2.3. Social Landscape
- 5.2.4. Technological Landscape
- 5.2.5. Environmental Landscape
- 5.2.6. Legal Landscape
5.3. PORTER's Five Forces
- 5.3.1. Bargaining power of suppliers
- 5.3.2. Bargaining power of buyers
- 5.3.3. Threat of Substitute
- 5.3.4. Threat of new entrant
- 5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Asia-Pacific In-Vitro Fertilization (IVF) Market

7. Asia-Pacific In-Vitro Fertilization (IVF) Market, By Cycle Type (USD Million)

7.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Value Share and Forecast, By Cycle Type, 2023-2033
7.2. Donor Egg IVF Cycle
7.3. Fresh Cycle (Non-Donor)
7.4. Thawed IVF Cycle (Non-Donor)

8. Asia-Pacific In-Vitro Fertilization (IVF) Market, By End User (USD Million)

8.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Value Share and Forecast, By End User, 2023-2033
8.2. Clinical Research Institutes
8.3. Fertility Clinics
8.4. Hospitals
8.5. Surgical Centers

9. Asia-Pacific In-Vitro Fertilization (IVF) Market Forecast, 2019-2033 (USD Million)

9.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share

10. Asia-Pacific In-Vitro Fertilization (IVF) Market, By Cycle Type, 2019-2033 (USD Million)

10.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By Cycle Type (2019-2026)
10.2. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By Cycle Type (2027-2033)

11. Asia-Pacific In-Vitro Fertilization (IVF) Market, By End User, 2019-2033 (USD Million)

11.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By End User (2019-2026)
11.2. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By End User (2027-2033)

12. Asia-Pacific In-Vitro Fertilization (IVF) Market, By Region, 2019-2033 (USD Million)

12.1. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By Region (2019-2026)
12.2. Asia-Pacific In-Vitro Fertilization (IVF) Market Size and Market Share By Region (2027-2033)
12.3. Australia
12.4. China
12.5. India
12.6. Indonesia
12.7. Japan
12.8. Malaysia
12.9. Myanmar
12.10. New Zealand
12.11. Philippines
12.12. Singapore
12.13. South Korea
12.14. Thailand
12.15. Vietnam
12.16. Rest of Asia-Pacific

13. Company Profile

13.1. Alcon
- 13.1.1. Company details
- 13.1.2. Financial outlook
- 13.1.3. Product summary
- 13.1.4. Recent developments
13.2. Bausch Health Companies Inc.
- 13.2.1. Company details
- 13.2.2. Financial outlook
- 13.2.3. Product summary
- 13.2.4. Recent developments
13.3. Carl Zeiss AG
- 13.3.1. Company details
- 13.3.2. Financial outlook
- 13.3.3. Product summary
- 13.3.4. Recent developments
13.4. Cooper Companies
- 13.4.1. Company details
- 13.4.2. Financial outlook
- 13.4.3. Product summary
- 13.4.4. Recent developments
13.5. Johnson & Johnson
- 13.5.1. Company details
- 13.5.2. Financial outlook
- 13.5.3. Product summary
- 13.5.4. Recent developments
13.6. MaxiVision Eye Hospital
- 13.6.1. Company details
- 13.6.2. Financial outlook
- 13.6.3. Product summary
- 13.6.4. Recent developments
13.7. Rayner Surgical Group Limited
- 13.7.1. Company details
- 13.7.2. Financial outlook
- 13.7.3. Product summary
- 13.7.4. Recent developments
13.8. Schwind eye-tech-solutions GmbH & co.kg.
- 13.8.1. Company details
- 13.8.2. Financial outlook
- 13.8.3. Product summary
- 13.8.4. Recent developments
13.9. STAAR Surgical Company
- 13.9.1. Company details
- 13.9.2. Financial outlook
- 13.9.3. Product summary
- 13.9.4. Recent developments
13.10. Ziemer Group AG
- 13.10.1. Company details
- 13.10.2. Financial outlook
- 13.10.3. Product summary
- 13.10.4. Recent developments
13.11. Others